Boyd Biomedical

04/02/2024

In biopharma, over the past few years, revenues from new-modality products increased by $60 billion. While revenues from conventional products declined by $10 billion.*

-

This is another important data point for biomedical innovators about the pace of technological advancement and market fragmentation.

The rate of technological change is now in a constant state of acceleration placing sustained pressure on product lifecycles.

There is enormous pressure to prioritize innovation and speed to market to capture development costs and profits.

-

This requires the capacity to continuously deliver new products in less time.

This has to come from both internal core competencies and external resources.

-

*Boston Consulting Group "Industry Report on New Drug Modalities"

04/02/2024

On Point: Life Sciences Industry

Bryan Dechairo on your future healthcare journey.

-

Large populations of consumers do not have access to diagnostics tests. Consumers with access have a bad user experience. Existing technologies don’t work.

Sherlock Biosciences, Inc. is inviting you to a new experience. Your future healthcare journey begins with accurate, affordable, accessible diagnostics tests.

Accurate - PCR level accuracy in a simple to use at home test.
Affordable - low-cost products you can buy at the drug store or online.
Accessible - simple and easy to use.

-

Watch this video
https://bit.ly/3Rcbwrw

Watch the full episode
https://bit.ly/47L87r4

MassMEDIC

03/31/2024

The Workflow & Process For Biomaterials In Life Sciences

In this article we discuss the workflow and process to design, development, and successfully commercialize biomaterials in life sciences applications.

03/28/2024

On Point: Innovation & Startups

Carmichael Roberts, co-founder and investor in Arsenal Medical on point sharing his insight on investing in what you know and the opportunities for investors in biomaterials innovation.

-
Watch the full episode
https://bit.ly/3Z8or1t

MassMEDIC

03/25/2024

On Point: Innovation & Startups

Carmichael Roberts, co-founder and investor in Arsenal Medical on point sharing his insight on investing in what you know and the opportunities for investors in biomaterials innovation.

-

Success dictates when things go wrong...not if. And the only way things don't go wrong is if your business fails fast.

Carmichael Roberts shares his philosophy for investing and explains why investors need to be able to be helpful and to be able to brainstorm around challenges when they occur.

We discuss whether there are enough people investing in biomaterials innovation and how large the field of investment opportunities is.

-

Watch this video
https://bit.ly/45DJT0L

Watch the full episode
https://bit.ly/3Lf3L1X

MassMEDIC

03/22/2024

Join us as we discover the remarkable progress in the field of biomaterials, powered by cutting-edge enabling technologies.

In this article we discuss how additive manufacturing, biofabrication, advanced characterization, computational modeling, and advanced materials are helping to revolutionize the design and fabrication of biomaterials, unlocking new possibilities in life sciences.

https://bit.ly/4622Ytq

We're advancing biomedical innovation through curiosity and shared knowledge.

Be curious.

03/21/2024

Companies that prioritize design outperform their competitors.

Effective product design isn't just about aesthetics; it's about creating user-centered solutions that resonate and deliver value. From intuitive interfaces to seamless experiences, design creates value and leaves a lasting impact.

Embrace the power of design to elevate your products.

Or as we say, go 'Best to Market'.

Learn more about our Design Services here
https://bit.ly/3LvXRtF

03/20/2024

On Point: Life Sciences Industry

Carmichael Roberts, co-founder and investor in Arsenal Medical on point sharing his founding vision for the Company.

-

Carmichael Roberts discusses the founding vision for Arsenal Medical which was to deliberately address biomedical applications that require both biochemical and structural solutions.

It was clear that if you could pick any two people to work on that solution that Bob Langer and George Whitesides would be the perfect combination - the "Reese's Peanut Butter Cup" - as Carmichael says.

They could bring together material science and biomedical innovation in a perfect and unique combination. So, that's what Arsenal did.

-

Watch this video:
https://bit.ly/3Z3NO4k

Watch the full episode:
https://bit.ly/3P4QN8e

MassMEDIC

03/19/2024

In this article we delve into key enabling technologies for biomaterials innovation in life sciences.

Join us as we explore additive manufacturing, biofabrication, advanced characterization, computational modeling, and advanced materials. Explore the impact these technologies have on the precision, customization, and possible applications of biomaterial constructs.

https://bit.ly/3RcLN3T

We're advancing biomedical innovation through curiosity and shared knowledge.

Be curious.

03/18/2024

According to the FDA,

"In 2022, CDER approved 37 novel drugs, either as new molecular entities (NMEs) under new drug applications (NDAs) or as new therapeutic biologics under biologics license applications (BLA).

Twenty (54%) of these novel drugs were first-in-class, meaning they have mechanisms of action different from those of existing therapies.

In addition, 20 (54%) of these approvals were for the treatment of rare or “orphan” diseases (diseases that affect fewer than 200,000 people in the U.S.)."

The availability of new technologies has led us into a period of extraordinary market fragmentation.

How corporations capture value has shifted from product-centric (mass-market) to customer-centric (masses of markets).

In order to capture that value we will need totally new systems of advanced manufacturing - check out more on that here - https://bit.ly/3EL2Cf5

03/15/2024

On Point: Innovation & Startups

Carmichael Roberts, co-founder and investor in Arsenal Medical on point sharing his perspective on the challenges and benefits for start-ups who attract government funding.

-

Investors can be split on whether or not you should accept government funding because of the rigorous process to get and maintain it. And even then, it can also influence your ongoing operations.

But, it can also be incredibly enabling and empowering if you can do it the right way.

Carmichael Roberts discusses DARPA's focus on innovation and their ability to help Arsenal Medical accelerate technology development which is a huge part of where Arsenal Medical is today.

-

Watch this video
https://bit.ly/3PqyCLC

Watch the full episode
https://bit.ly/3PrFtEp

MassMEDIC

03/14/2024

Join us as we look at the dynamic landscape of biomaterials innovation. Explore the interplay between biomaterials and additive manufacturing, biofabrication, advanced characterization, computational modeling, and advanced materials.

https://bit.ly/48gV8xY

Uncover the impact of these technologies on fascinating biomedical innovations like tissue engineering and drug delivery systems.

We're advancing biomedical innovation through curiosity and shared knowledge.

Be curious.